Public Employees Retirement System of Ohio Invests $1.49 Million in Intellia Therapeutics, Inc. $NTLA

Key Points

• Public Employees Retirement System of Ohio acquired 88,257 Intellia Therapeutics shares worth approximately $1.49 million, joining institutional investors that collectively own 88.77% of NTLA.
• Analyst sentiment is mixed: the stock has an average rating of “Hold” and an average price target of $21.15, while individual targets range from $25 to $30 alongside a “sell” rating.
• Intellia reported a quarterly loss of $0.80 per share, in line with estimates, but revenue of $7.66 million fell short of expectations and declined 46.4% year over year. Shares opened at $12.74, well below the 52-week high of $28.25.

Public Employees Retirement System of Ohio acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 88,257 shares of the company's stock, valued at approximately $1,493,000. Public Employees Retirement System of Ohio owned about 0.06% of Intellia Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Comerica Bank lifted its position in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company's stock valued at $26,000 after acquiring an additional 901 shares during the period. PNC Financial Services Group Inc. boosted its stake in Intellia Therapeutics by 36.4% during the first quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company's stock worth $46,000 after acquiring an additional 948 shares in the last quarter. Wealthfront Advisers LLC grew its holdings in Intellia Therapeutics by 7.6% in the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company's stock worth $185,000 after purchasing an additional 1,018 shares during the period. Benjamin Edwards Inc. grew its holdings in Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company's stock worth $591,000 after purchasing an additional 1,126 shares during the period. Finally, Axxcess Wealth Management LLC increased its stake in shares of Intellia Therapeutics by 6.1% during the first quarter. Axxcess Wealth Management LLC now owns 22,707 shares of the company's stock valued at $291,000 after purchasing an additional 1,308 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the sale, the chief accounting officer directly owned 66,886 shares in the company, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president directly owned 156,286 shares of the company's stock, valued at approximately $2,813,148. The trade was a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NTLA shares. HC Wainwright reiterated a "buy" rating and set a $25.00 target price on shares of Intellia Therapeutics in a report on Monday, June 15th. Citigroup restated a "market outperform" rating on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. Citizens Jmp reaffirmed a "market outperform" rating and set a $30.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, August 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. Finally, New Street Research set a $25.00 target price on Intellia Therapeutics in a report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have issued a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $21.15.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $12.74 on Tuesday. The firm has a market cap of $1.79 billion, a P/E ratio of -3.79 and a beta of 1.82. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The firm has a 50-day simple moving average of $12.86 and a two-hundred day simple moving average of $13.42.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The firm had revenue of $7.66 million for the quarter, compared to the consensus estimate of $12.98 million. During the same quarter in the prior year, the firm posted ($0.98) earnings per share. The business's revenue was down 46.4% on a year-over-year basis. On average, equities research analysts predict that Intellia Therapeutics, Inc. will post -3.21 EPS for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.